Evidence suggests that the AKT1 gene may modulate the degree to which cannabis use induces cognitive alterations in patients with a psychotic disorder.
Aim:
To examine the interplay between AKT1 and cannabis use in terms of the cognitive performance of the general population.
Methods:
Our sample consisted of 389 Spanish university students. Sustained attention was measured via the Continuous Performance Test–Identical Pairs, immediate and delayed verbal memory with the Logical Memory subtest of the Wechsler Memory Scale, and working memory with the Wisconsin Card Sorting Test. Lifetime cannabis use frequency was assessed and individuals were classified as cannabis users or non-users. Two single nucleotide polymorphisms of the AKT1 gene were genotyped and, according to previous studies, each subject was defined as a carrier of two, one or no copies of the haplotype (rs2494732(C)–rs1130233(A)). Multiple linear regressions were conducted to test the effect of the genetic variability and cannabis use (and their interaction) on cognitive performance.
Results:
An effect of the AKT1 haplotype was found on attention scores: individuals with two copies of the haplotype performed better (β=0.18, p<0.001 (adjusted for false discovery rate)), while neither cannabis nor the AKT1–cannabis interaction was associated with attention. No effect of AKT1, cannabis or the AKT1–cannabis interaction was found on verbal memory or working memory.
Conclusions:
Our study provides additional evidence that AKT1 modulates cognitive performance. However, in our non-clinical sample, the previously reported interaction between cannabis use and the AKT1 gene was not replicated.
AbecasisGRAutonABrooksLD, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature491: 56–65.
2.
BajestanSNSabouriAHNakamuraM, et al. (2006) Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet Part B: Neuropsychiatr Genet141B: 383–386.
3.
BarrettJCFryBMallerJ, et al. (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics21: 263–265.
4.
BeaulieuJ-MGainetdinovRRCaronMG (2007a) The Akt–GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci28: 166–172.
5.
BeaulieuJ-MTirottaESotnikovaTD, et al. (2007b) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci27: 881–885.
6.
BeckerMPCollinsPFSchultzA, et al. (2018) Longitudinal changes in cognition in young adult cannabis users. J Clin Exp Neuropsychol40: 529–543.
7.
BenjaminiYHochbergY (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc57: 289–300.
8.
BhattacharyyaSAtakanZMartin-SantosR, et al. (2012) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry17: 1152–1155.
9.
BhattacharyyaSIyegbeCAtakanZ, et al. (2014) Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychol Med44: 3315–3328.
10.
BlasiGNapolitanoFUrsiniG, et al. (2011) DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA108: 1158–1163.
11.
BloklandGAMMesholam-GatelyRIToulopoulouT, et al. (2017) Heritability of neuropsychological measures in schizophrenia and nonpsychiatric populations: A systematic review and meta-analysis. Schizophr Bull43: 788–800.
12.
BroydSJvan HellHHBealeC, et al. (2016) Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiatry79: 557–567.
13.
Castellanos-RyanNPingaultJ-BParentS, et al. (2017) Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Dev Psychopathol29: 1253–1266.
14.
CornblattBARischNJFarisG, et al. (1988) The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res26: 223–238.
15.
CoskerESchwitzerTRamozN, et al. (2018) The effect of interactions between genetics and cannabis use on neurocognition. A review. Prog Neuropsychopharmacol Biol Psychiatry82: 95–106.
16.
CousijnJWiersRWRidderinkhofKR, et al. (2014) Effect of baseline cannabis use and working-memory network function on changes in cannabis use in heavy cannabis users: A prospective fMRI study. Hum Brain Mapp35: 2470–2482.
17.
D’SouzaDCAbi-SaabWMMadonickS, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry57: 594–608.
18.
DaviesGTenesaAPaytonA, et al. (2011) Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol Psychiatry16: 996–1005.
19.
Di FortiMIyegbeCSallisH, et al. (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry72: 811–816.
EdwardsACBacanuS-ABigdeliTB, et al. (2016) Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res176: 136–140.
22.
EmamianESHallDBirnbaumMJ, et al. (2004) Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nature Genet36: 131–137.
23.
FirstMBSpitzerRGibbonM, et al. (1999) Entrevista Clínica Estructurada Para Los Trastornos Del Eje I Del DSM-IV (SCID-I). Barcelona: Masson.
24.
FreybergZFerrandoSJJavitchJA (2010) Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry167: 388–396.
25.
González-PintoAGonzález-OrtegaIAlberichS, et al. (2016) Opposite cannabis-cognition associations in pychotic patients depending on family history. PLoS One11: e0160949.
26.
GräffJMansuyIM (2008) Epigenetic codes in cognition and behaviour. Behav Brain Res192: 70–87.
27.
GreenMFKernRSHeatonRK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res72: 41–51.
28.
GreenwoodTABraffDLLightGA, et al. (2007) Initial heritability analyses of endophenotypic measures for schizophrenia: The consortium on the genetics of schizophrenia. Arch Gen Psychiatry64: 1242–1250.
29.
GreenwoodTALazzeroniLCCalkinsME, et al. (2016) Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res170: 30–40.
30.
GreenwoodTALazzeroniLCMaihoferAX, et al. (2019) Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry76: 1274.
31.
HaworthCMAWrightMJLucianoM, et al. (2010) The heritability of general cognitive ability increases linearly from childhood to young adulthood. Mol Psychiatry15: 1112–1120.
32.
HeatonRK (1981) Wisconsin Card Sorting Test: Computer Version - 2. Research Edition. Odessa, FL: Psychological Assessment Resources, Inc.
33.
HenquetCKrabbendamLSpauwenJ, et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ330: 11.
34.
HenquetCRosaAKrabbendamL, et al. (2006) An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology31: 2748–2757.
35.
HowellKRLawAJ (2019) Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development. Schizophr Res. Epub ahead of print 15 September 2019. DOI: 10.1016/J.SCHRES.2019.08.036.
36.
IkedaMIwataNSuzukiT, et al. (2004) Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry56: 698–700.
37.
KaregeFMéaryAPerroudN, et al. (2012) Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes. Schizophr Res135: 8–14.
38.
KaregeFPerroudNSchürhoffF, et al. (2010) Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder. Genes Brain Behav9: 503–511.
39.
KeefeRSEHarveyPD (2012) Cognitive impairment in schizophrenia. In: GeyerMGrossG (eds) Novel Antischizophrenia Treatments. Handbook of Experimental Pharmacology, vol 213. Berlin, Heidelberg: Springer, pp. 11–37.
40.
KlausKPenningtonK (2019) Dopamine and Working Memory: Genetic Variation, Stress and Implications for Mental Health. In: HodgsonT (ed) Processes of Visuospatial Attention and Working Memory. Current Topics in Behavioral Neurosciences. Cham: Springer, pp. 369–391.
41.
KochhannRGonçalvesHAPurezaJdaR, et al. (2017) Variability in neurocognitive performance: Age, gender, and school-related differences in children and from ages 6 to 12. Appl Neuropsychol Child1–9.
42.
KoningsMBakMHanssenM, et al. (2006) Validity and reliability of the CAPE: A self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand114: 55–61.
43.
MarconiADi FortiMLewisCM, et al. (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull42: 1262–1269.
44.
MarkWToulopoulouT (2016) Cognitive intermediate phenotype and genetic risk for psychosis. Curr Opin Neurobiol36: 23–30.
45.
MaxwellE (1992) Family Interview for Genetic Studies (FIGS): A manual for FIGS. Bethesda, MD: Clinical Neurogenetics Branch, Intramural Research Program, National Institute of Mental Health.
46.
MeijerJHDekkerNKoeterMW, et al. (2012) Cannabis and cognitive performance in psychosis: A cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol Med42: 705–716.
47.
MinozziSDavoliMBargagliAM, et al. (2010) An overview of systematic reviews on cannabis and psychosis: Discussing apparently conflicting results. Drug Alcohol Rev29: 304–317.
48.
MooreTHZammitSLingford-HughesA, et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet370: 319–328.
49.
MorganCJAFreemanTPPowellJ, et al. (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry6: e738.
50.
MurrayRMMorrisonPDHenquetC, et al. (2007) Cannabis, the mind and society: The hash realities. Nat Rev Neurosci8: 885–895.
51.
NaderDASanchezZM (2018) Effects of regular cannabis use on neurocognition, brain structure, and function: A systematic review of findings in adults. Am J Drug Alcohol Abuse44: 4–18.
52.
NortonNWilliamsHJDwyerS, et al. (2007) Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res93: 58–65.
53.
NúñezCOchoaSHuerta-RamosE, et al. (2016) Cannabis use and cognitive function in first episode psychosis: Differential effect of heavy use. Psychopharmacology233: 809–821.
54.
O’ReillyRC (2006) Biologically based computational models of high-level cognition. Science314: 91–94.
55.
OhiKHashimotoRYasudaY, et al. (2013) The AKT1 gene is associated with attention and brain morphology in schizophrenia. World J Biol Psychiatry14: 100–113.
56.
OzaitaAPuighermanalEMaldonadoR (2007) Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem102: 1105–1114.
57.
PietiläinenOPHPaunioTLoukolaA, et al. (2009) Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins. Am J Med Genet Part B: Neuropsychiatr Genet150B: 683–692.
58.
RabinRAZakzanisKKGeorgeTP (2011) The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res128: 111–116.
59.
RipkeSNealeBMCorvinA, et al. (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature511: 421–427.
60.
Ros-MorenteAVilagra-RuizRRodriguez-HansenG, et al. (2011) Process of adaptation to Spanish of the Community Assessment of Psychic Experiences (CAPE). Actas Esp Psiquiatr39: 95–105.
61.
SánchezMGRuiz-LlorenteLSánchezAM, et al. (2003) Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal15: 851–859.
62.
Sánchez-TorresAMBasterraVRosaA, et al. (2013) Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings. Eur Arch Psychiatry Clin Neurosci263: 643–653.
63.
SattlerJM (2001) Assessment of Children: Cognitive Applications. 4th ed.La Mesa, CA: Jerome M. Sattler Publisher.
ScheidMPWoodgettJR (2003) Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett546: 108–112.
66.
SchoelerTKambeitzJBehlkeI, et al. (2016) The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychol Med46: 177–188.
67.
ScholesKEMartin-IversonMT (2010) Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med40: 1635–1646.
68.
SchwabSGHoefgenBHansesC, et al. (2005) Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry58: 446–450.
69.
SeamansJKYangCR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol74: 1–58.
70.
SegevALev-RanS (2012) Neurocognitive functioning and cannabis use in schizophrenia. Curr Pharm Des18: 4999–5007.
71.
StefanisNCHanssenMSmirnisNK, et al. (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med32: 347–358.
72.
SwerdlowNRGurREBraffDL (2015) Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of Schizophrenia Research. Schizophr Res163: 9–16.
73.
TanHYChenAGKolachanaB, et al. (2012) Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain135: 1436–1445.
74.
TanH-YChenQGoldbergTE, et al. (2007) Catechol-O-methyltransferase Val158Met modulation of prefrontal parietal striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci27: 13393–13401.
75.
TanH-YNicodemusKKChenQ, et al. (2008) Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest118: 2200–2208.
76.
ThamesADArbidNSayeghP (2014) Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav39: 994–999.
77.
ThiseltonDLVladimirovVIKuoP-H, et al. (2008) AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry63: 449–457.
78.
Van OsJBakMHanssenM, et al. (2002) Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol156: 319–327.
79.
Van WinkelRKahnRSLinszenDH, et al. (2011a) Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Arch Gen Psychiatry68: 148–157.
80.
Van WinkelRvan BeverenNJMSimonsC, et al. (2011b) AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology36: 2529–2537.
81.
VerdouxHGindreCSorbaraF, et al. (2003) Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychol Med33: 23–32.
82.
WechslerD (1997a) Wechsler Adult Intelligence Scale. 3rd ed (WAIS-III). Administration and Scoring Manual., (Adaptación Española: (1999) TEA Ediciones, Madrid., San Antonio, TX: Psychological Corporation.
XuM-QXingQ-HZhengY-L, et al. (2007) Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry68: 1358–1367.
85.
YucelMBoraELubmanDI, et al. (2012) The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull38: 316–330.
